In MM, several anti-BCMA CAR T cell therapies have shown impressive clinical activities (some reaching 90–100%) with more are developed and under preclinical and/or clinical investigations (see Table 1). This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.